SecBot SecBot
SECBOTREPLAY Home › Report › RCUS

RCUS · Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121…

Arcus Biosciences, Inc. · 8-K filed Apr 20, 2026 at 07:56 ET

At the news

BEARISHIMPACT 8/10

8-K filed Apr 20, 2026 at 07:56 ET

Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 trial in metastatic non-small cell lung cancer due to futility, based on an independent data monitoring committee's recommendation. Additionally, Gilead will not extend its option rights to Arcus's early-stage pipeline programs beyond July 14, 2026, retaining only limited existing options.

  • Phase 3 STAR-121 study evaluating domvanalimab + zimberelimab + chemo vs. pembrolizumab + chemo in first-line metastatic NSCLC discontinued due to futility
  • Decision based on pre-planned futility analysis by Independent Data Monitoring Committee (IDMC); safety not assessed at this stage
  • Exploratory endpoint showed zimberelimab + chemo performed consistently with pembrolizumab + chemo on overall survival
  • Phase 2 EDGE-Lung study also being discontinued

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access